VioQuest Pharmaceuticals, Inc. 2006 Management Bonus Plans Summary

Summary

VioQuest Pharmaceuticals, Inc. established 2006 bonus plans for key executives, including the CEO, CFO, General Manager of Chiral Quest Inc., and other senior leaders. Bonuses are awarded based on achieving specific milestones such as successful financings, clinical trial progress, product acquisitions, regulatory filings, and financial targets. Additional bonuses are tied to qualitative performance factors like leadership and teamwork. Each executive has a maximum eligible bonus amount, with payouts contingent on meeting the outlined goals within the 2006 calendar year.

EX-10.1 2 v044219_ex10-1.htm Unassociated Document
Exhibit 10.1

VioQuest Pharmaceuticals, Inc.
Summary of 2006 Management Bonus Plans

Daniel Greenleaf
President & Chief Executive Officer

Milestone
 
Bonus Amount
 
Completion of financings resulting in gross proceeds of a targeted amount
 
$
50,000
 
Listing of common stock on national exchange or Nasdaq
   
50,000
 
Initiation of 3 clinical trials in the U.S. of Company product candidates under Company-sponsored INDs
   
30,000
 
Completion of 3 clinical trials in the U.S. of Company product candidates under Company-sponsored INDs
   
30,000
 
Acquisition of new compound, as approved by the Board
   
30,000
 
Chiral Quest net loss less than a targeted amount and revenues in excess of a targeted amount
   
20,000
 
Acceptance of NDA filing for review for leishmaniasis indication for VQD-001
   
15,000
 
Qualitative factors based on leadership, teamwork, peer interaction, initiative and communication
   
25,000
 
TOTAL MAXIMUM ELIGIBLE BONUS
 
$
250,000
 

Michael Cannarsa, Ph.D.
General Manager, Chiral Quest Inc.

Milestone
 
Bonus Amount
 
2006 Chiral Quest net loss less than a targeted amount
 
$
18,000
 
2006 Chiral Quest revenue at least at a targeted amount and margin equal to or greater than a targeted percentage
   
18,000
 
Completion of targeted number of strategic transactions
   
7,200
 
Qualitative factors based on leadership, teamwork, peer interaction, initiative and communication
   
4,800
 
TOTAL MAXIMUM ELIGIBLE BONUS
 
$
48,000
 

Pamela Jo Harris, M.D.

Milestone
 
Bonus Amount
 
Initiation of Phase I in VQD-001
 
$
1,875
 
Completion of Phase I in VQD-001
   
4,375
 
Initiation of Phase I in VQD-002 for solid tumors
   
1,875
 
Completion of Phase I in VQD-002 for solid tumors
   
4,375
 
Initiation of Phase I in VQD-002 for hematological malignancies
   
1,875
 
Completion of Phase I in VQD-002 for hematological malignancies
   
4,375
 
NDA filing for VQD-001 for leishmaniasis indication
   
3,750
 
Qualitative factors based on leadership, teamwork, peer interaction, initiative and communication
   
2,500
 
TOTAL MAXIMUM ELIGIBLE BONUS
 
$
25,000
 



Brian Lenz
Chief Financial Officer

Milestone
 
Bonus Amount
 
Completion of financings resulting in gross proceeds of a targeted amount
 
$
13,500
 
Initiation of 3 clinical trials
   
3,825
 
Completion of non-dilutive financings resulting in proceeds of at least targeted amounts
   
5,625
 
Listing of common stock on national exchange or Nasdaq
   
9,675
 
Chiral Quest net loss less than a targeted amount
   
7,875
 
Qualitative factors based on leadership, teamwork, peer interaction, initiative and communication
   
4,500
 
TOTAL MAXIMUM ELIGIBLE BONUS
 
$
45,000
 

Richard Welter, Ph.D.
Vice President of Corporate Business Development

Milestone
 
Bonus Amount
 
Company’s acquisition of clinical compound, as approved by the Board (reduced by half if compound is pre-clinical)
 
$
25,000
 
Initiation of 3 clinical trials
   
5,000
 
Completion of 3 patient enrollment trials
   
5,000
 
Acceptance of NDA filing for review for leishmaniasis indication for VQD-001
   
10,000
 
Qualitative factors based on leadership, teamwork, peer interaction, initiative and communication
   
5,000
 
TOTAL MAXIMUM ELIGIBLE BONUS
 
$
50,000